Trial Profile
A clinical study of combining etoposide and apatinib to cure recurrence and transfer of small cell lung
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2017
Price :
$35
*
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 01 Apr 2017 New trial record